The U.S. Food and Drug Administration has accepted Eisai Co.'s supplemental biologics license application for LEQEMBI IQLIK, a subcutaneous autoinjector ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE